Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU).

被引：3
|
作者：
Hagiwara, May
Park, Jinhee
Delea, Thomas E.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e21068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21068
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF PAZOPANIB VERSUS SUNITINIB AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Espinosa, J.
    Gonzalez-Larriba, J. L.
    Maroto, P.
    Mendez-Vidal, M. J.
    Diaz-Cerezo, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A632 - A633
  • [2] Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).
    Iacovelli, Roberto
    Derosa, Lisa
    Massari, Francesco
    Verri, Elena
    Galli, Luca
    Ciccarese, Chiara
    Rocca, Maria Cossu
    Cianci, Claudia
    Bimbatti, Davide
    Aurilio, Gaetano
    Antonuzzo, Andrea
    Fantinel, Emanuela
    Cullura, Daniela
    Ricci, Sergio
    Modena, Alessandra
    Falcone, Alfredo
    Tortora, Giampaolo
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    [J]. JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [4] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [6] Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Cella, David
    Davis, Mellar P.
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Hahn, Elizabeth A.
    Korytowsky, Beata
    Bhattacharyya, Helen
    Sandin, Rickard
    Beaumont, Jennifer L.
    Matczak, Ewa
    Motzer, Robert John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) patients in the United States
    Nakhaipour, Hamid Reza
    Dales, Tom
    Amdahl, Jordan
    Diaz, Jose
    Hackshaw, Michelle Denise
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345